RxDoctor Payments Data

Steven Cullen, MD

Internal Medicine · San Clemente, CANPI 1487765731

Payments from drug & device makers

$609in general payments, 2019–2025

Across 26 payments — averaging $23.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$199
  • Lilly USA, LLC$186
  • Amgen$43
  • AbbVie$42
  • Novo Nordisk$39
  • Merck$24
  • plus $77 from 5 others

What the payments were for

  • Food & beverage$609100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson7$199
Lilly USA, LLC5$186
Amgen3$43
AbbVie2$42
Novo Nordisk2$39
Merck1$24
GSK2$24
Concordia Pharmaceuticals Inc.1$18
Exact Sciences1$18
Genentech USA, Inc.1$13
Biomerieux Inc1$5

How this compares

$609 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$216,468
Medicare patients
256
Services billed
2,123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban33$33,044
EliquisApixaban39$30,418
Solu-CortefHydrocortisone Sodium Succ/Pf11$5,261
Fentanyl14$2,083
Gabapentin115$1,625
Rosuvastatin Calcium117$1,482
Risedronate Sodium22$1,473
Celecoxib35$1,418
Testosterone14$1,292
Metoprolol Succinate86$1,196
Atorvastatin Calcium147$1,172
Levothyroxine Sodium155$1,108
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen53$1,102
Pantoprazole Sodium73$1,019
Memantine Hcl20$798

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$199$33,04433 claims
Lilly USA, LLCOlanzapine$186$39013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Clemente

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →